ランキング価格はじめての方へ
  1. 米国企業
  2. EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.EYPT

時価総額
$3.1億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2012年
6月30日		2013年
6月30日		2014年
6月30日		2015年
6月30日		2016年
6月30日		2017年
6月30日		2018年
6月30日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日
Net loss-------53-57-45-58-102
Amortization of intangible assets21111112332
Impairment of intangible assets15---------21
Depreciation0000000000396,000
Amortization of debt discount and premium and discount on available-for-sale marketable securities-----------1
Paid-in-Kind Interest-------11--
Loss (gain) on extinguishment of debt--------4-12-2
Inventory Write-down---------12
Stock-based compensation111222356714
Accounts receivable and other current assets-------15-5113
Inventory-------23-11
Accounts payable and accrued expenses-------5281
Right-of-use assets and operating lease liabilities-------00-00
Deferred revenue--------017-1-1
Net cash used in operating activities-9-9-----22-57-14-50-65
Purchases of marketable securities15831018----33139
Sales and maturities of marketable securities1514---19----124
Purchases of property and equipment00000000002
Net cash used in investing activities16-----17-0-0-33-17
Proceeds From Issuance Of Stock And Pre Funded Warrants Net Of Issuance Costs---------217-
Proceeds from issuance of long-term debt------2050--30
Payment of equity and debt issue costs----------1
Payment of long-term debt-------2014-38
Payment of extinguishment of debt costs-------31-2
Proceeds from Lines of Credit----------44
Repayment under revolving facility----------33
Net settlement of stock units to satisfy statutory tax withholding-------0000
Proceeds from Stock Options Exercised--100010000
Principal payments on finance lease obligations--------00137,000
Net cash (used in) provided by financing activities05----613437217-1
Effect of foreign exchange rate changes on cash and cash equivalents------00---
Net (decrease) increase in cash, cash equivalents and restricted cash------22-2323134-83
Cash interest paid------05653
Stock issuance costs---------0-
Debt Instrument Exit Fee-------30-1
Payments forgiven under paycheck protection program loan---------2-